Pathogenesis, diagnosis and management of hepatitis C

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 98-112

  Boyer, Nathalie ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Genotype; HCV RNA; Hepatitis C; Interferon; Quasispecies; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; ENZYME INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 12; MACROGOL; RIBAVIRIN; RIBOZYME;

ALCOHOL CONSUMPTION; CHRONIC LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNE SYSTEM; RNA, VIRAL;

EID: 0034092720     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80419-5     Document Type: Article

References (122)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. Marcellin P. Hepatitis C: clinical spectrum of the disease. J Hepatol 1999; 31 (Suppl. 1): 9-16.
3. Hoofnagle JH, Mullen KD, Jones DB, RustDi V, Di Biscoglie AD, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575-8.
4. Gonzalez-Peralta RP, Davis GL, Lau JY. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255-9.
5. Lerat H, Berby F, Trabaud MA, Vidalin O, Major M, Trepo C, et al. Specific detection of hepatitis C minus strand RNA in haematopoietic cells. J Clin Invest 1996; 97: 845-51.
6. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
7. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494-500.
8. Farci P, Alter HJ, Wong DC. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-6.
9. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
10. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Ohkoshi S, Shimotohno K. Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun 1991; 175: 220-8.
11. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Gastroenterology 1999; 117: 408-13.
12. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-7.
13. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-71.
14. Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, et al. Compartmentalization of T-lymphocytes to the site of the disease: intrahepatic CD4+ T-cells specific for the protein NS4 of hepatitis C virus i n patients with chronic hepatitis C. J Exp Med 1993; 178: 17-25.
15. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996; 24: 759-65.
16. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
17. Zeuzem S, Franka A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 1003-9.
18. Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, et al. Detection and quantitation of serum hepatitis C virus (HCV) RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994; 20: 676-8.
19. Gervais A, Martinot M, Boyer N, Pouteau M, Castelnau C, Degott C, et al. The severity of histologic lesions is not related to liver HCV RNA level in patients with chronic hepatitis C. J Hepatol 1998; 28: 117 (Abstract).
20. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, and the Collaborative Study Group. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-8.
21. Silini E, Bottelili R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case control study. Gastroenterology 1996; 111: 199-205.
22. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997; 25: 211-5.
23. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after transplantation. Gastroenterology 1995; 108: 1088-96.
24. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JYN, Simmonds P, et al. Severity of liver disease in liver transplant recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996; 24.: 1014-6.
25. Gane EJ, Portman BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long term outcome of hepatitis C infection after liver transplantation? N Engl J Med 1996; 334: 815-20.
26. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patients and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
27. Féray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619-25.
28. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzàlez J, Pedreira J, Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999; 31 (Suppl. 1): 119-23.
29. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
30. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27: 1717-22.
31. Wiley TE, McCarthy M, Breidi L, Mc Carthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805-9.
32. Donato F, Tagger A, Chiesa R, Ribeiro ML, Tomazoni V, Fasola M, Gelatti U, et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Hepatology 1997; 26: 579-84.
33. Oshita T, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 20: 1115-20.
34. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
35. Pagliaro L, Peri V, Linea C, Cammà C, Guinta M, Magrin S. Natural history of chronic hepatitis C. Ital J Gastroenterol Hepatol 1999; 31: 28-44.
36. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-905.
37. Kenny-Wlash E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33.
38. Gervais A, Bacq A, Bernuau J, Martinot M, Aupérin A, Boyer N, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000 (in press).
39. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675-81.
40. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT Association between HLA class II genotype and spontaneous clearance of hepatitis C viremia. J Hepatol 1998; 29: 207-13.
41. Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998; 27: 1700-2.
42. Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997; 26 (Suppl 1): 43S-47S.
43. Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C infection. Hepatology 1992; 16: 877-81.
44. Marcellin P, Martinot-Peignoux M, Elias A, Branger M, Courtois F, Level R, et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 1994; 170; 433-5.
45. van der Poel CL. Hepatitis C virus and blood transfusion: past and present risks. J Hepatol 1999; 31 (Suppl. 1): 101-6.
46. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999; 30: 956-61.
47. French Study Group for the Standardization of Hepatitis C Virus PCR. Improvement of hepatitis C virus RNA polymerase chain reaction through a multicentre quality control study. J Virol Methods 1994; 49: 79-88.
48. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med 1996; 124: 1058-60.
49. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997; 127: 875-81.
50. Loriot MA. Marcellin P, Bismuth E, Martinot-Peignoux M, Boyer N, Degott C, et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in serum and liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992; 15: 32-6.
51. Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, Mondelli M, Zarski JP, et al. Detection of genomic and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Hepatology 1999; 29: 536-42.
52. Brody RI, Eng S, Melamed J, Mizrachi H, Schneider RJ, Tobias H, et al. Immunohistochemical detection of hepatitis C antigen by monoclonal antibody TORDJI-22 compared with PCR viral detection. Am J Clin Pathol 1998; 110: 32-7.
53. Martinot-Peignoux M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998; 29: 214-23.
54. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
55. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
56. Simmonds P, Alberti A, Alter H, Bonino F, Bardley DW, Bréchot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 191 321-24.
57. Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. J Hepatol 1999; 31 (Suppl. 1): 65-70.
58. Pawlotsky JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 1734-9.
59. Lee JH, Stripf T, Roth WK, Zeuzem S. Non-isotopic detection of hepatitis C virus quasispecies by single strand conformation polymorphism. J Med Virol 1997; 53: 245-51.
60. Gonzalez-Peralta RP, Quian K, She JY, Davis GL, Ohno T, Mizokamii M, et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49: 242-7.
61. Le Guen B, Squadrito G, Nalpas B, Berthelot P, Pol S, Bréchot C. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 1997; 25: 1250-4.
62. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, et al. Genetic complexity of the hypervariable region 1 (HVR 1) of hepatitis C virus. Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998; 54: 256-64.
63. Asselah T, Martinot-Peignoux M, Levy S, Martins-Amado V, Marcellin P. Hypervariable region 1 (HVR1) quasispecies in patients with chronic hepatitis C and normal ALT. J Hepatol 1999; 30: 121 (Abstract).
64. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, et al. Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 1994; 68: 3425-36.
65. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Ann Gastroenterol 1995; 90: 1250-7.
66. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numeral scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981; 1: 431-5.
67. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
68. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7: 690-713.
69. Bedossa P, Poynard T. The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
70. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 226: 347-56.
71. Foster GR. Hepatitis C virus infection: quality of life and side effects. J Hepatol 1999; 31 (Suppl. 1): 250-4.
72. Manabé N, Chevallier M, Chossegros P, Causse X, Guerret S, Trépo C, et al. Interferon-alpha2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993; 8: 1344-9.
73. Duchatelle V, Marcellin P, Giostra E, Pouteau M, Auperin A, Guerret S, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assement by a morphometric method. J Hepatol 1998; 29: 20-8.
74. National Institutes of Health Consensus Development Conference. Panel statement: management of hepatitis C. Hepatology 1997; 26 (Suppl 1): 2S-10S.
75. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
76. Marcellin P, Boyer N, Martinot M, Erlinger S. Interferon therapy in hepatitis C: benefits and limitations. In: Arroyo V, Bosch J, Bruguera M, Rodès J, editors. Therapy in liver diseases. The pathophysiological basis of therapy. Barcelona: Masson; 1997. p. 309.
77. Keeffe EB, Hollinger FB and the Consensus Interferon Study Group. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997; 26 (Suppl 1): 101S-107S.
78. Lindsay KL. Treatment of chronic hepatitis C: Comparative virological response rates among the different interferons. J Hepatol 1999; 31 (Suppl. 1): 232-6.
79. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
80. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 152-9.
81. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-8.
82. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Rivabirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
83. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribarivin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7.
84. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307-12.
85. Reichard O, Norkrans G, Fryden A, Braconier JH, Sönnerborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
86. Weiland O. Treatment of naive patients with chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 168-73.
87. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997; 27 (Suppl. 1): 137S-142S.
88. Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V et al. Retreatment with interferon alpha of patients with chronic hepatitis C. Hepatology 1998; 27: 1144-8.
89. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trépo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
90. Marcellin P, Hezode C, Castelnau C, Barange K, Couzigou P, Larrey D, et al. Randomized controlled trial of combination therapy with interferon (IFN) alpha-2a and ribavirin, in patients with chronic hepatitis C who relapsed after interferon therapy. Hepatology 1999; 30 (Suppl 2): 192A (Abstract).
91. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23 (Suppl. 2): 17-21.
92. Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, et al. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999; 31: 1-7.
93. Schalm SW, Brouwer JT, Bekkering FC, van Rossum TGJ. New treatment strategies in patients with chronic hepatitis C non responders. J Hepatol 1999; 31 (Suppl. 1): 184-8.
94. Brillanti S, Foli M, Di Tomasso M, Gramantieri L, Masci C, Bolondi L. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alfa non-responders. Ital J Gastroenterol Hepatol 1999; 31: 130-4.
95. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997; 26 (Suppl. 1): 128S-132S.
96. Valla D, Chevallier M, Marcellin P, Payen JL, Trépo C, Fonck M, et al. Treatment of hepatitis C virus-related cirrhosis. A randomized controlled trial of interferon alpha-2b versus non treatment. Hepatology 1999; 29: 1870-5.
97. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
98. International Interferon-α Hepatocellular Carcinoma Study Group, Brunetto MR, Oliverti F, Koehler M. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535-9.
99. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
100. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
101. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1997; 26 (Suppl. 1): 133S-137S.
102. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999; 31 (Suppl. 1): 189-92.
103. Marcellin P, Boyer N, Benhamou JP, Erlinger S. Interferon-α therapy for chronic hepatitis C in special populations. Dig Dis Sci 1936; 41 (Suppl): 126S-130S.
104. Zoulim F. Hepatitis C virus infection in special groups. J Hepatol 1999; 31 (Suppl. 1): 130-5.
105. Pol S, Zylberberg H, Fontaine H, Brechot C. Treatment of chronic hepatitis C in special groups. J Hepatol 1999; 31 (Suppl. 1): 205-9.
106. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study ol the combination of alpha interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500-4.
107. Zein NN, Rakela J, Krawitt EL, Reddy R, Tominaga T, Persing DH and the Collaborative Study Group. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Intern Med 1996; 125: 634-9.
108. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. J Viral Hepatitis 1999; 6: 435-43.
109. Civeira M-P, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999 (in press).
110. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
111. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-27.
112. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C geno-type 1 virus with interferon alpha. Hepatology 1997; 26: 226-31.
113. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis. 1999; 19 (Suppl 1): 25-33.
114. Shiffman ML, Pockros PJ, Reddy RK, Wright TL, Reindollar R, Clin C, et al. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alpha-2A (PEG) vs standard interferon alpha-2A (IFN) for treatment of chronic hepatitis C. Gastroenterology 1999; 116 (Suppl): A1275 (Abstract).
115. Love RA, Parge HE, Wickersham JA, Hotomsky Z, Hubuka N, Moomaw EW, et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87: 331-42.
116. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide (published erratum appears in Cell 1997; Apr 4; 89(1):159). Cell 1996; 87: 343-55.
117. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4: 463-7.
118. von Weizsacker F, Wieland S, Kock J, Offensperger WB, Offensperger S, Moradpour D, et al. Gene therapy for chronic viral hepatitis: ribozymes antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-5.
119. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998; 10: 163-71.
120. Abrignani S, Houghton M, Hsu HH. Perspective for a vaccine against hepatitis C virus. J Hepatol 1999; 31 (Suppl. 1): 259-63.
121. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-8.
122. Inchauspe G. Major ME, Nakano I, Vivitski L, Maisonnas M, Trépo C. Immune responses against hepatitis C virus structural proteins following genetic immunisation. Dev Biol Stand 1998; 92: 163-8.